Loading...
Header Logo
Keywords
Last Name
Institution

DEBASISH TRIPATHY

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zhao H, Shen J, Moore SC, Ye Y, Wu X, Esteva FJ, Tripathy D, Chow WH. Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. Breast Cancer Res Treat. 2019 08; 176(3):697. PMID: 31154579.
      View in: PubMed
    2. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel). 2019 May 24; 11(5). PMID: 31137625.
      View in: PubMed
    3. Whisenant MS, Strunk FA, Tripathy D, Williams LA. What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer. Support Care Cancer. 2019 Apr 02. PMID: 30937601.
      View in: PubMed
    4. Zhao H, Shen J, Moore SC, Ye Y, Wu X, Esteva FJ, Tripathy D, Chow WH. Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. Breast Cancer Res Treat. 2019 Aug; 176(3):687-696. PMID: 30771047.
      View in: PubMed
    5. Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM. Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Mol Cancer Ther. 2019 02; 18(2):399-412. PMID: 30518672.
      View in: PubMed
    6. Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol. 2018 Aug; 35:69-76. PMID: 29843069.
      View in: PubMed
    7. Edwards BJ, Zhang X, Sun M, Holmes HM, Ketonen L, Guha N, Khalil P, Song J, Kesler S, Shah JB, Tripathy D, Valero V, Champlin RE. Neurocognitive deficits in older patients with cancer. J Geriatr Oncol. 2018 09; 9(5):482-487. PMID: 29530493.
      View in: PubMed
    8. Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget. 2018 Jan 23; 9(6):6872-6882. PMID: 29467936.
      View in: PubMed
    9. Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. 2018 May; 26(5):1561-1568. PMID: 29197959.
      View in: PubMed
    10. Tripathy D, Bardia A, Sellers WR. Mechanism of Action and Clinical Impact of Ribociclib-Response. Clin Cancer Res. 2017 09 15; 23(18):5658. PMID: 28916619.
      View in: PubMed
    11. Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017 Sep 01; 3(9):1266-1273. PMID: 28301631.
      View in: PubMed
    12. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662. PMID: 28928852.
      View in: PubMed
    13. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400.
      View in: PubMed
    14. Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clin Cancer Res. 2017 07 01; 23(13):3251-3262. PMID: 28351928.
      View in: PubMed
    15. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.
      View in: PubMed
    16. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347.
      View in: PubMed
    17. Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9. PMID: 27138575.
      View in: PubMed
    18. Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res. 2016 08; 31(8):1569-76. PMID: 26896384.
      View in: PubMed
    19. Silberman H, Sheth PA, Parisky YR, Hovanessian-Larsen LJ, Sheth S, Tripathy D. Modified Bi-Rads Scoring of Breast Imaging Findings Improves Clinical Judgment. Breast J. 2015 Nov-Dec; 21(6):642-50. PMID: 26411901.
      View in: PubMed
    20. Tripathy D. The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care. BMC Med. 2015 Sep 23; 13:223. PMID: 26394747.
      View in: PubMed
    21. Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez-MacGregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153(2):417-23. PMID: 26272743.
      View in: PubMed
    22. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative. J Cancer. 2015; 6(7):610-5. PMID: 26078790.
      View in: PubMed
    23. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol. 2015 Jul 10; 33(20):2239-45. PMID: 25987700.
      View in: PubMed
    24. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686.
      View in: PubMed
    25. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14. PMID: 25605252.
      View in: PubMed
    26. Greenlee H, Zick SM, Rosenthal D, Cohen L, Cassileth B, Tripathy D. Integrative oncology - strong science is needed for better patient care. Nat Rev Cancer. 2015 Mar; 15(3):165. PMID: 25693833.
      View in: PubMed
    27. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31. PMID: 25432738.
      View in: PubMed
    28. Lang JE, Wecsler JS, Press MF, Tripathy D. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. J Surg Oncol. 2015 Jan; 111(1):81-90. PMID: 25091830.
      View in: PubMed
    29. Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27; 110(11):2756-64. PMID: 24743708.
      View in: PubMed
    30. Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):725-34. PMID: 24706168.
      View in: PubMed
    31. Dieli-Conwright CM, Mortimer JE, Schroeder ET, Courneya K, Demark-Wahnefried W, Buchanan TA, Tripathy D, Bernstein L. Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods. BMC Cancer. 2014 Apr 03; 14:238. PMID: 24708832.
      View in: PubMed
    32. Lee SC, Jain PA, Jethwa SC, Tripathy D, Yamashita MW. Radiologist's role in breast cancer staging: providing key information for clinicians. Radiographics. 2014 Mar-Apr; 34(2):330-42. PMID: 24617682.
      View in: PubMed
    33. Kim M, Agarwal S, Tripathy D. Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. Curr Opin Obstet Gynecol. 2014 Feb; 26(1):27-33. PMID: 24335887.
      View in: PubMed
    34. Tripathy D, Durie BG, Mautner B, Ferenz KS, Moul JW. Awareness, concern, and communication between physicians and patients on bone health in cancer. Support Care Cancer. 2014 Jun; 22(6):1601-10. PMID: 24477326.
      View in: PubMed
    35. Mehta A, Tripathy D. Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast. 2014 Feb; 23(1):2-9. PMID: 24176518.
      View in: PubMed
    36. Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):461-70. PMID: 24062208.
      View in: PubMed
    37. Baniwal SK, Chimge NO, Jordan VC, Tripathy D, Frenkel B. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PLoS One. 2014; 8(6):e62361. PMID: 23755096.
      View in: PubMed
    38. Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10. PMID: 23652380.
      View in: PubMed
    39. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. PMID: 23470967.
      View in: PubMed
    40. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      View in: PubMed
    41. Jiang L, Weatherall PT, McColl RW, Tripathy D, Mason RP. Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study. J Magn Reson Imaging. 2013 May; 37(5):1083-92. PMID: 23124705.
      View in: PubMed
    42. Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012 Oct; 135(3):875-83. PMID: 22923238.
      View in: PubMed
    43. Perez EA, Burris HA, Mooberry S, Tripathy D. New treatment paradigms for optimizing survival in advanced and metastatic breast cancer. Clin Adv Hematol Oncol. 2012 Aug; 10(8 Suppl 13):1-14; quiz 15-6. PMID: 23072876.
      View in: PubMed
    44. Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L. Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer. J Med Internet Res. 2012 Jul 11; 14(4):e97. PMID: 22784878.
      View in: PubMed
    45. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. PMID: 22649152.
      View in: PubMed
    46. Tripathy D. Breast cancer quality care: what is at stake? Breast J. 2012 May-Jun; 18(3):201-2. PMID: 22583193.
      View in: PubMed
    47. Tripathy D. Using neoadjuvant therapy for breast cancer in clinical practice: when and how? Breast Cancer Res Treat. 2012 Apr; 132(3):775-7. PMID: 22438051.
      View in: PubMed
    48. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. PMID: 22198468.
      View in: PubMed
    49. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res. 2011; 13(6):R127. PMID: 22151997.
      View in: PubMed
    50. Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res. 2012 Feb 01; 18(3):901-11. PMID: 22147940.
      View in: PubMed
    51. Tripathy D. PARP inhibitors: the story is still unfolding. Oncology (Williston Park). 2011 Oct; 25(11):1028, 1030. PMID: 22106553.
      View in: PubMed
    52. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9. PMID: 21796368.
      View in: PubMed
    53. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul 15; 17(14):4834-43. PMID: 21768129.
      View in: PubMed
    54. Langford DJ, Paul SM, Tripathy D, West C, Dodd MJ, Schumacher K, Miaskowski C. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain during participation in a psychoeducational intervention study to improve pain management. J Pain. 2011 Jun; 12(6):652-66. PMID: 21429811.
      View in: PubMed
    55. Langford DJ, Tripathy D, Paul SM, West C, Dodd MJ, Schumacher K, Miaskowski C. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain. 2011 Apr; 12(4):495-507. PMID: 21310669.
      View in: PubMed
    56. Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Clin Breast Cancer. 2010 Dec 01; 10(6):421-39. PMID: 21147685.
      View in: PubMed
    57. Tripathy D. FDA and Avastin: crossroads in an era of targeted therapies. Oncology (Williston Park). 2010 Oct; 24(11):989-90. PMID: 21155445.
      View in: PubMed
    58. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Feb; 120(1):111-8. PMID: 20054647.
      View in: PubMed
    59. Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman RJ, Klimberg VS, Kuske R, Levine GM, Linver MN, Rafferty EA, Rugo H, Schilling K, Tripathy D, Vicini FA, Whitworth PW, Willey SC. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg. 2009 Oct; 209(4):504-20. PMID: 19801324.
      View in: PubMed
    60. Block KI, Gyllenhaal C, Tripathy D, Freels S, Mead MN, Block PB, Steinmann WC, Newman RA, Shoham J. Survival impact of integrative cancer care in advanced metastatic breast cancer. Breast J. 2009 Jul-Aug; 15(4):357-66. PMID: 19470134.
      View in: PubMed
    61. Tripathy D. Are we hitting the right combination for hormonally sensitive breast cancer? J Clin Oncol. 2009 Jun 01; 27(16):2580-2. PMID: 19380439.
      View in: PubMed
    62. Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer. 2008 Feb; 8(1):33-7. PMID: 18501057.
      View in: PubMed
    63. Ranganathan A, Muneer S, Cunningham S, Shivakumar L, Tripathy D. Highlights from: The 24th Annual Miami Breast Cancer Conference; Miami, FL; March 14-17, 2007. Support Cancer Ther. 2007 May 01; 4(3):137-44. PMID: 18632479.
      View in: PubMed
    64. Zhang M, Liu X, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev. 2007 Apr 18; (2):CD004921. PMID: 17443560.
      View in: PubMed
    65. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage. 2007 Apr; 33(4):462-72. PMID: 17397707.
      View in: PubMed
    66. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist. 2007 Apr; 12(4):375-89. PMID: 17470680.
      View in: PubMed
    67. Tripathy D. Cardiac side effects of trastuzumab: lessons learned from targeting cancer pathways. Nat Clin Pract Oncol. 2007 Apr; 4(4):220-1. PMID: 17342070.
      View in: PubMed
    68. Miaskowski C, Dodd M, West C, Paul SM, Schumacher K, Tripathy D, Koo P. The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management. Pain. 2007 May; 129(1-2):55-63. PMID: 17257753.
      View in: PubMed
    69. Villars P, Dodd M, West C, Koetters T, Paul SM, Schumacher K, Tripathy D, Koo P, Miaskowski C. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage. 2007 Jan; 33(1):67-77. PMID: 17196908.
      View in: PubMed
    70. Deng GE, Cassileth BR, Cohen L, Gubili J, Johnstone PA, Kumar N, Vickers A, Abrams D, Rosenthal D, Sagar S, Tripathy D. Integrative Oncology Practice Guidelines. J Soc Integr Oncol. 2007; 5(2):65-84. PMID: 17511932.
      View in: PubMed
    71. Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat. 2007 Sep; 105(1):17-28. PMID: 17111207.
      View in: PubMed
    72. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17361-5. PMID: 17079488.
      View in: PubMed
    73. Guo J, Zhou AW, Fu YC, Verma UN, Tripathy D, Frenkel EP, Becerra CR. Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacol Sin. 2006 Oct; 27(10):1375-81. PMID: 17007746.
      View in: PubMed
    74. Body JJ, Diel IJ, Tripathy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl). 2006 Jul; 15(3):299-302. PMID: 16882128.
      View in: PubMed
    75. McLachlan SA, Cameron D, Murray R, Tripathy D, Bergström B. Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. Clin Drug Investig. 2006; 26(1):43-8. PMID: 17163234.
      View in: PubMed
    76. Silverstein MJ, Lagios MD, Recht A, Allred DC, Harms SE, Holland R, Holmes DR, Hughes LL, Jackman RJ, Julian TB, Kuerer HM, Mabry HC, McCready DR, McMasters KM, Page DL, Parker SH, Pass HA, Pegram M, Rubin E, Stavros AT, Tripathy D, Vicini F, Whitworth PW. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg. 2005 Oct; 201(4):586-97. PMID: 16183499.
      View in: PubMed
    77. Kwak YT, Li R, Becerra CR, Tripathy D, Frenkel EP, Verma UN. IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J Biol Chem. 2005 Oct 07; 280(40):33945-52. PMID: 16103118.
      View in: PubMed
    78. Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2005 Jun; 6(2):150-7. PMID: 16001993.
      View in: PubMed
    79. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81. PMID: 15908529.
      View in: PubMed
    80. Schumacher KL, Koresawa S, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. Qualitative research contribution to a randomized clinical trial. Res Nurs Health. 2005 Jun; 28(3):268-80. PMID: 15884025.
      View in: PubMed
    81. Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D. Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer. 2005 Apr; 6(1):45-54. PMID: 15899072.
      View in: PubMed
    82. Tripathy D. Targeted therapies in breast cancer. Breast J. 2005 Mar-Apr; 11 Suppl 1:S30-5. PMID: 15725114.
      View in: PubMed
    83. Westermann AM. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2005 Mar; 16(3):513; author reply 513. PMID: 15668265.
      View in: PubMed
    84. Osborne C, Tripathy D. Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med. 2005; 56:103-16. PMID: 15660504.
      View in: PubMed
    85. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004 Dec 15; 10(24):8152-62. PMID: 15623589.
      View in: PubMed
    86. Tripathy D, Body JJ, Bergström B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther. 2004 Dec; 26(12):1947-59. PMID: 15823760.
      View in: PubMed
    87. Kim JE, Dodd M, West C, Paul S, Facione N, Schumacher K, Tripathy D, Koo P, Miaskowski C. The PRO-SELF pain control program improves patients' knowledge of cancer pain management. Oncol Nurs Forum. 2004 Nov 16; 31(6):1137-43. PMID: 15547636.
      View in: PubMed
    88. Utkan G, Büyükçelik A, Yalçyn B. The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer. Ann Oncol. 2004 Oct; 15(10):1574; author reply 1574-5. PMID: 15367420.
      View in: PubMed
    89. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergström B. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004 Oct; 111(3):306-12. PMID: 15363874.
      View in: PubMed
    90. Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2004 Oct; 5(4):293-8. PMID: 15507176.
      View in: PubMed
    91. Tripathy A D, Diel I, Body JJ. Ibandronate reduces skeletal morbidity in patients with breast cancer. Semin Oncol. 2004 Oct; 31(5 Suppl 10):64-6. PMID: 15490378.
      View in: PubMed
    92. Edrington JM, Paul S, Dodd M, West C, Facione N, Tripathy D, Koo P, Schumacher K, Miaskowski C. No evidence for sex differences in the severity and treatment of cancer pain. J Pain Symptom Manage. 2004 Sep; 28(3):225-32. PMID: 15336334.
      View in: PubMed
    93. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Martino S, Tripathy D, Ingle JN, Wood WC. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 01; 101(5):969-72. PMID: 15329905.
      View in: PubMed
    94. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9393-8. PMID: 15194824.
      View in: PubMed
    95. Block KI, Cohen AJ, Dobs AS, Ornish D, Tripathy D. The challenges of randomized trials in integrative cancer care. Integr Cancer Ther. 2004 Jun; 3(2):112-27. PMID: 15165498.
      View in: PubMed
    96. Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, Koo P. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol. 2004 May 01; 22(9):1713-20. PMID: 15117994.
      View in: PubMed
    97. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004 May; 15(5):743-50. PMID: 15111341.
      View in: PubMed
    98. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004 Mar 22; 90(6):1133-7. PMID: 15026791.
      View in: PubMed
    99. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70. PMID: 15020607.
      View in: PubMed
    100. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004; 9(4):361-77. PMID: 15266090.
      View in: PubMed
    101. Tripathy D. Systemic therapy for advanced breast cancer. Breast J. 2004 Jan-Feb; 10 Suppl 1:S26-7. PMID: 14984487.
      View in: PubMed
    102. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003 Sep; 14(9):1399-405. PMID: 12954579.
      View in: PubMed
    103. Tripathy D. Clinical testing of supplementation therapy in early stage breast cancer: pitfalls and opportunities. Integr Cancer Ther. 2003 Jun; 2(2):160-2. PMID: 15035905.
      View in: PubMed
    104. Tripathy D. Biologically targeted therapy: as good as advertized? Clin Breast Cancer. 2003 Jun; 4(2):89. PMID: 12864934.
      View in: PubMed
    105. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. PMID: 12637463.
      View in: PubMed
    106. West CM, Dodd MJ, Paul SM, Schumacher K, Tripathy D, Koo P, Miaskowski C. The PRO-SELF(c): Pain Control Program--an effective approach for cancer pain management. Oncol Nurs Forum. 2003 Jan-Feb; 30(1):65-73. PMID: 12515985.
      View in: PubMed
    107. Tripathy D. Multidisciplinary care for breast cancer: barriers and solutions. Breast J. 2003 Jan-Feb; 9(1):60-3. PMID: 12558678.
      View in: PubMed
    108. Cohen I, Tagliaferri M, Tripathy D. Traditional Chinese medicine in the treatment of breast cancer. Semin Oncol. 2002 Dec; 29(6):563-74. PMID: 12516039.
      View in: PubMed
    109. Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D. Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res. 2002 Nov-Dec; 22(6C):3843-52. PMID: 12553004.
      View in: PubMed
    110. Schumacher KL, Koresawa S, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. The usefulness of a daily pain management diary for outpatients with cancer-related pain. Oncol Nurs Forum. 2002 Oct; 29(9):1304-13. PMID: 12370700.
      View in: PubMed
    111. Tripathy D. Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer. 2002 May; 3 Suppl 1:8-11. PMID: 12057038.
      View in: PubMed
    112. Schumacher KL, Koresawa S, West C, Hawkins C, Johnson C, Wais E, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. Putting cancer pain management regimens into practice at home. J Pain Symptom Manage. 2002 May; 23(5):369-82. PMID: 12007755.
      View in: PubMed
    113. Tripathy D. Gemcitabine in breast cancer: future directions. Clin Breast Cancer. 2002 May; 3 Suppl 1:45-8. PMID: 12057046.
      View in: PubMed
    114. Schumacher KL, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski CA. Pain management autobiographies and reluctance to use opioids for cancer pain management. Cancer Nurs. 2002 Apr; 25(2):125-33. PMID: 11984100.
      View in: PubMed
    115. Block KI, Constantinou A, Hilakivi-Clarke L, Hughes C, Tripathy D, Tice JA. Point-counterpoint: soy intake for breast cancer patients. Integr Cancer Ther. 2002 Mar; 1(1):90-100. PMID: 14664752.
      View in: PubMed
    116. Miaskowski C, Mack KA, Dodd M, West C, Paul SM, Tripathy D, Koo P, Schumacher K, Facione N. Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control. J Pain. 2002 Feb; 3(1):12-20. PMID: 14622849.
      View in: PubMed
    117. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26. PMID: 11821453.
      View in: PubMed
    118. Miaskowski C, Dodd MJ, West C, Paul SM, Tripathy D, Koo P, Schumacher K. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol. 2001 Dec 01; 19(23):4275-9. PMID: 11731509.
      View in: PubMed
    119. Tripathy D. Bisphosphonates in oncology: breast cancer and beyond. Semin Oncol. 2001 Aug; 28(4 Suppl 11):86-91. PMID: 11544583.
      View in: PubMed
    120. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59. PMID: 11456056.
      View in: PubMed
    121. Tagliaferri M, Cohen I, Tripathy D. Complementary and alternative medicine in early-stage breast cancer. Semin Oncol. 2001 Feb; 28(1):121-34. PMID: 11254871.
      View in: PubMed
    122. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9. PMID: 11167088.
      View in: PubMed
    123. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42. PMID: 11694786.
      View in: PubMed
    124. Sepucha KR, Belkora JK, Tripathy D, Esserman LJ. Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer. J Clin Oncol. 2000 Mar; 18(6):1230-8. PMID: 10715292.
      View in: PubMed
    125. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48. PMID: 10561337.
      View in: PubMed
    126. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999 Aug; 26(4 Suppl 12):78-83. PMID: 10482197.
      View in: PubMed
    127. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 Aug; 16(8):2659-71. PMID: 9704716.
      View in: PubMed
    128. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996 Mar; 14(3):737-44. PMID: 8622019.
      View in: PubMed
    129. Tripathy D. How long should adjuvant tamoxifen be continued? Oncology (Williston Park). 1994 Oct; 8(10):25-33; discussion 33, 37-8. PMID: 7803214.
      View in: PubMed
    130. Tripathy D, Benz C. Growth factors and their receptors. Hematol Oncol Clin North Am. 1994 Feb; 8(1):29-50. PMID: 8150783.
      View in: PubMed
    131. Tripathy D, Henderson IC. Systemic adjuvant therapy for breast cancer. Curr Opin Oncol. 1992 Dec; 4(6):1041-9. PMID: 1457518.
      View in: PubMed
    132. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95. PMID: 8095168.
      View in: PubMed
    133. Tripathy D, Benz CC. Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. Cancer Treat Res. 1992; 63:15-60. PMID: 1363356.
      View in: PubMed
    134. Tripathy D, Coleman RA, Vidaillet HJ, Steenbergen C, Hirschhorn K, Packer DL. Complete heart block with myocardial membrane-bound glycogen and normal peripheral alpha-glucosidase activity. Ann Intern Med. 1988 Dec 15; 109(12):985-7. PMID: 3057987.
      View in: PubMed
    135. Antibody dependent cell-mediated cytotoxicity (adcc) of an anti-her2 antibody requires opsonization of tumor target. FASEB Journal. 10.
    136. PARP inhibitors. Oncology. 25.
    137. Strategies to evaluate the clinical potential of botanical agents for breast cancer. Breast Cancer Research and Treatment. 69:304.
    138. Traditional Chinese medicine in the treatment of breast cancer (Part two). Journal of Chinese Medicine. 49-53.
    139. Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer. Breast Diseases. 18:205-206.
    140. Traditional Chinese medicine in the treatment of breast cancer (Part one). Journal of Chinese Medicine. 40-49.
    141. Traditional Chinese medicine in the treatment of breast cancer. Journal of Chinese Medicine. 44-54.
    142. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. Oncotarget. 6:44623-44634.
    143. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer. Journal of Clinical Oncology. 34:2602-2609.
    144. Looking ahead to rational combinatorial therapy. Community Oncology. 9:40-41.
    145. Time to begin adjuvant chemotherapy and survival in breast cancer patients. Breast Diseases. 25:271-273.
    146. Biological therapy of breast cancer. BioDrugs. 14:221-246.
    147. Double-blind randomized 12-month soy intervention had no effects on breast MRI fibroglandular tissue density or mammographic density. Cancer Prevention Research. 8:942-951.
    148. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Annals of Surgical Oncology. 1-7.
    149. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Research and Treatment. 160:101-109.
    150. Highlights from. Clinical Breast Cancer. 7:535-536.
    151. Effect of cardiac dysfunction on treatment outcome in the Herceptin (trastuzumab) pivotal trial. Breast Cancer Research and Treatment. 69:303.
    152. Highlights from. Clinical Breast Cancer. 7:539-542.
    153. Medical oncology analysis. Integrative Cancer Therapies. 5:375-378.
    154. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 7:76362-76373.
    155. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Breast Diseases. 15:319-320.
    156. The BMC Medicine breast cancer collection. BMC Medicine. 13.
    157. Location of receipt of initial treatment and outcomes in long-term breast cancer survivors. PLoS One. 12.
    158. Erratum. Journal of Biological Chemistry. 280:38888.
    159. Adjuvant Trastuzumab. Breast Diseases. 17:120-121.
    160. RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer. Nature Communications. 7.
    161. Peer viewpoint. Journal of Supportive Oncology. 2:427-428.
    162. Oral daily ibandronate. European Journal of Cancer, Supplement. 2:17-20.
    163. HERMIONE. BMC Cancer. 16.
    164. First-line treatment with bevacizumab and paclitaxel prolongs progression-free survival in metastatic breast cancer. Clinical Breast Cancer. 6:105-107.
    165. The neoadjuvant model is still the future for drug development in breast cancer. Clinical Cancer Research. 21:2911-2915.
    166. 3-49 Adjuvant Docetaxel or Vinorelbine With or Without Trastuzumab for Breast Cancer. Breast Diseases. 17:278-280.
    167. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database of Systematic Reviews.
    168. Escalation of oncologic services at the end of life among patients with gynecologic cancer at an urban, public hospital. Journal of Oncology Practice. 11:e163-e169.
    169. Adjuvant Aromatase Inhibitors. Breast Diseases. 18:132-133.
    170. Value-Based Breast Cancer Care. Annals of Surgical Oncology. 1-6.
    171. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. British Journal of Cancer.
    172. The Rabinowitz article reviewed. Oncology. 18:1270-1275.
    173. Highlights of the 2015 San Antonio Breast Cancer Symposium. Genes and Diseases. 3:110-113.
    174. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Breast Diseases. 16:15-16.
    175. Zebra hunting. Clinical Breast Cancer. 7:655.
    176. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Breast Diseases. 19:81-83.
    177. Breast cancer advocacy in clinical care. Breast Disease. 10:3-14.
    178. Making a difference in refractory breast cancer. Community Oncology. 8:17-19.
    179. FDA and avastin. Oncology. 24.
    180. Introduction. Clinical Breast Cancer. 3.
    181. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. Breast Diseases. 15:376-377.
    182. Dietary fat reduction improves relapse-free survival in postmenopausal women previously treated for early-stage breast cancer. Clinical Breast Cancer. 6:112-114.
    183. Highlights from. Clinical Breast Cancer. 8:313-321.
    184. New serum markers. Oncology. 22.
    185. Value of routine staging imaging studies for patients with stage III breast cancer. Journal of Surgical Oncology.
    186. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. Breast Diseases. 15:196-198.
    187. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Breast Diseases. 23:88-89.
    188. Complementary and alternative medicine in breast cancer. Breast Diseases. 15:368-369.
    189. Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases. Molecular Cancer Therapeutics. 14:2687-2699.
    190. Highlights from. Clinical Breast Cancer. 7:536-538.
    191. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. Breast Diseases. 23:284-285.
    192. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Research and Treatment. 1-12.
    193. Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. Journal of Cancer. 6:610-615.
    194. Complementary and alternative medicine in breast cancer. 787-796.
    195. T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with Trastuzumab and Pertuzumab. Journal of Clinical Oncology. 34:3511-3517.
    196. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. Breast Diseases. 19:80-81.
    197. Highlights from. Clinical Breast Cancer. 7:538-539.
    TRIPATHY's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description